Imatinib as Second-Line Treatment Drug for CML Patients Intolerant to Nilotinib.
- VernacularTitle:伊马替尼治疗尼洛替尼不耐受的慢性髓系白血病
- Author:
Jing QI
1
;
You-Hai XU
1
;
He-Sheng HE
2
,
3
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome
- From: Journal of Experimental Hematology 2018;26(2):407-411
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the individualized treatment for patient with chronic phase chronic myeloid leukemia(CML-CP).
METHODSThe clinical data and treatment process of one CML-CP patient which intolerated to nilotinib were analyzed.
RESULTSNilotinib was given to the patient once the diagnosis of CML-CP was set. Although major molecular remission (MMR) and complete cytogenetic remission (CCyR) were obtained during treatment for 3 months, a grade 3-4 hepatotoxicity appeared in the course of treatment.With drug reduction and symptomatic treatment, nilotinib was discontinued after 3 withdrawals and replaced with imatinib in January 11, 2015. The patients achieved MMR and CCyR at 7 months after imatinib replacement. At present, the patient tolerated well without any adverse events.
CONCLUSIONImatinib can be used as a second-line treatment drug for CML patients who was intolerant to nilotinib, and with less adverts, good effect and so on.
